 |
 |
ZADAXIN®: New Promise in Cancer
Treatment
A healthy immune system is critical for a patient to become a long-term
survivor of cancer. Unfortunately, both cancer itself and the drugs used
to treat it often cause immunosuppression, leaving the body vulnerable
to opportunistic infections and further cancer invasion. ZADAXIN energizes
the immune response, helping patients to battle invasive cancers and secondary
infections.
Now, ZADAXIN energizes the fight against cancer. |
 |
Liver Cancer
More than 100,000 new cases of hepatocellular carcinoma (HCC, or liver
cancer) are diagnosed each year. When HCC is diagnosed at an early stage,
patients can be treated by surgical resection or liver transplantion.
Unfortunately, most patients will not be diagnosed until their tumor has
grown too large to be cured. Until recently, these patients could only
expect to receive palliative treatment such as radio-frequency ablation,
chemotherapy, or transcatheter arterial chemoembolization.
Now, adding ZADAXIN to transcatheter arterial chemoembolization (TACE):
| • |
Doubles
survival at 7 months after end of treatment compared to historical,
non–ZADAXIN-treated controls
(1) |
| • |
Significantly
increases survival at 3, 6, 9, and 12 months compared to controls
(2) |
| • |
Significantly
increases both CD3 and CD8 cells 3 months after beginning
treatment (P = 0.05,
P = 0.025) (1) |
| • |
Significantly
increases NK cells after 1 month (P< 0.05)
(1) |
|
End-of-Treatment
Response Viral RNA (1)
• PCR Response • 6 Month
Rx • 75% Genotype (1) |
|
|
Malignant Melanoma
Malignant melanoma is the fastest-growing cancer today. Early detection
is not always possible, which gives the cancer time to metastasize. Currently,
patients face surgery, chemotherapy, radiation therapy, and extremely
low 5-year survival rates.
Now, adding ZADAXIN to DTIC plus IFN malignant melanoma therapy:
| • |
More than doubles the historical
response to DTIC alone |
| • |
Shows a 50% overall response rate,
mean response durations of 11.5 to 13.5 months
(3,4) |
| • |
Provides 35% survival after 1 year
(4)
|
|
Malignant Melanoma
ZADAXIN treatment following DTIC with IL-2 provides a 36% overall
response rate with 11-month median survival time.
(5)
Back to top |
Increasing
Response Rates With ZADAXIN
DTIC alone
(Falkson)
|
DTIC/IFN
(Garbe) |
DTIC/IL2
(Flaherty) |
ZDX/IL2/
DTIC
(Lopez) |
ZDX/IFN/
DTIC
(Favalli) |
ZDX/IFN/
DTIC
(Rasi) |
|
|
Non–Small-Cell Lung Cancer
Every year, lung cancer claims more lives than breast, colorectal, and
prostate cancer combined. Today, most unresectable NSCLC is treated with
radiation, chemotherapy, or a combination thereof, which may add debilitating
side effects to an already deteriorating quality of life.
| • |
Following
radiation therapy with ZADAXIN treatment for up to 12 months
significantly improves relapse-free survival (P = 0.04) and
overall survival (P = 0.009). (9) |
| • |
Adding
ZADAXIN to IFN, cisplatin, and etoposide provides a 44% overall
response rate and a 12.6-month median survival time. (10) |
| • |
Treatment with
ZADAXIN, IFN, and ifosfamide triples the response rate compared
to ifosfamide alone and doubles the time to progression (P
= 0.006). (11) |
|
Response Rates
Following Treatment (8) |
|
Improving Quality of Life
In all ZADAXIN cancer trials conducted to date, ZADAXIN has been extremely
well tolerated and has not added to the side-effect profile associated
with TACE, DTIC, ifosfamide, or IFN. Additionally, of more than 3,000
patients treated in all ZADAXIN clinical trials worldwide, less than 1%
experienced ZADAXIN-related adverse events.* |
Reaching the World
Approved in more than 25 countries.
*Adverse experiences have been infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash.
References: 1. Stephanini GF, et al. Hepatogastroenterology. 1998;45:209-215. 2. Li ZS. Presentation at the Shanghai International Oncology Conference, April
2001. 3. Favalli C. Presentation at the Third International Symposium on Combination Therapies, Houston, Texas, 1993. 4. Rasi G, et al. Melanoma Res.
2000;10:189-192. 5. Lopez M, et al. Ann Oncol. 1994;5:741-746. 6. Falkson C, et al. Proceedings of the American Association of Cancer Research.
1990;31:A1185. 7. Garbe C, et al. Semin in Oncol. 1992;19:63-69. 8. Flaherty L, et al. Cancer. 1990:65:2471-2477. 9. Schulof RS, et al. J Biol Response Mod.
1985;4:147-158. 10. Lopez M, et al. Presentation at the Third International Symposium on Combination Therapies, Houston, Texas, 1993. 11. Salvati F, et al.
Anticancer Res. 1996;16:1001-1004.
Back to top |
|
